Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canakinumab in Alcoholic Hepatitis
NCT03775109Phase 2Completed
- Sponsor
- Imperial College London
- Start
- Feb 2019
- Primary completion
- Mar 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcoholic hepatitis (AH) comparing Canakinumab with Placebo (2 arms). Primary endpoint: Histological Improvement of Alcoholic Hepatitis on Liver Biopsy at 28 days. Started Feb 2019; status: completed.
02
Drugs
canakinumab
03
Conditions
alcoholic hepatitis (AH)
Beyond the preview
Go deeper on NCT03775109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03775109.